As Conmed Corporation (CNMD) Market Value Rose, Champlain Investment Partners LLC Has Trimmed Its Stake

CONMED Corporation (NASDAQ:CNMD) LogoInvestors sentiment decreased to 1.18 in Q2 2019. Its down 0.60, from 1.78 in 2019Q1. It worsened, as 20 investors sold CNMD shares while 64 reduced holdings. 32 funds opened positions while 67 raised stakes. 30.45 million shares or 20.13% less from 38.12 million shares in 2019Q1 were reported. Verition Fund Management Limited Liability holds 20,793 shares or 0.05% of its portfolio. J Goldman And Lp holds 0.97% or 162,771 shares in its portfolio. Federated Invsts Inc Pa owns 220,940 shares or 0.05% of their US portfolio. Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys reported 8,895 shares stake. Rech Invsts, California-based fund reported 2.27 million shares. Carroll Fincl Associates Inc has 38 shares. State Of Tennessee Treasury Department stated it has 16,136 shares. Amundi Pioneer Asset Mgmt owns 1,800 shares or 0% of their US portfolio. Atria Invests Ltd Liability holds 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 26,850 shares. Credit Suisse Ag stated it has 24,445 shares or 0% of all its holdings. Point72 Asset Ltd Partnership has 0.33% invested in CONMED Corporation (NASDAQ:CNMD) for 740,076 shares. Metropolitan Life Co New York holds 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 8,632 shares. Blackrock holds 0.01% or 4.09M shares in its portfolio. Public Employees Retirement Association Of Colorado reported 0% in CONMED Corporation (NASDAQ:CNMD). Robeco Institutional Asset Mngmt Bv, Netherlands-based fund reported 4,422 shares.

Champlain Investment Partners Llc decreased its stake in Conmed Corporation (CNMD) by 5% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc sold 87,336 shares as the company’s stock rose 9.52% . The institutional investor held 1.66M shares of the electromedical & electrotherapeutic apparatus company at the end of 2019Q2, valued at $87.11M, down from 1.75 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Conmed Corporation for a number of months, seems to be less bullish one the $2.69B market cap company. The stock increased 1.53% or $1.43 during the last trading session, reaching $95.02. About 150,821 shares traded. CONMED Corporation (NASDAQ:CNMD) has risen 19.51% since October 12, 2018 and is uptrending. It has outperformed by 19.51% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04B and $8.47 billion US Long portfolio, upped its stake in Mccormick & Company Incorpora (NYSE:MKC) by 318,275 shares to 512,455 shares, valued at $52.60M in 2019Q2, according to the filing. It also increased its holding in Logmein Inc. (NASDAQ:LOGM) by 328,561 shares in the quarter, for a total of 1.37M shares, and has risen its stake in Prestige Brands Holdings Inc. (NYSE:PBH).

Analysts await CONMED Corporation (NASDAQ:CNMD) to report earnings on November, 7. They expect $0.56 EPS, up 21.74 % or $0.10 from last year’s $0.46 per share. CNMD’s profit will be $15.84M for 42.42 P/E if the $0.56 EPS becomes a reality. After $0.56 actual EPS reported by CONMED Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent CONMED Corporation (NASDAQ:CNMD) news were published by: which released: “Dirk Kuyper to Step Down from CONMED Corporation Board of Directors Effective August 1, 2019 – Business Wire” on June 18, 2019, also with their article: “Did Hedge Funds Drop The Ball On Seritage Growth Properties (SRG) ? – Yahoo Finance” published on April 30, 2019, published: “Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates – Yahoo Finance” on July 31, 2019. More interesting news about CONMED Corporation (NASDAQ:CNMD) were released by: and their article: “CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates – Yahoo Finance” published on August 01, 2019 as well as‘s news article titled: “Did Hedge Funds Drop The Ball On Matador Resources Co (MTDR) ? – Yahoo Finance” with publication date: April 30, 2019.

CONMED Corporation (NASDAQ:CNMD) Ratings Coverage

Among 3 analysts covering Conmed (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conmed has $11000 highest and $92 lowest target. $100.33’s average target is 5.59% above currents $95.02 stock price. Conmed had 5 analyst reports since April 15, 2019 according to SRatingsIntel. The stock of CONMED Corporation (NASDAQ:CNMD) has “Buy” rating given on Thursday, August 1 by Stifel Nicolaus. The rating was maintained by Barclays Capital with “Overweight” on Monday, April 15. Piper Jaffray upgraded the shares of CNMD in report on Thursday, August 22 to “Overweight” rating.

CONMED Corporation (NASDAQ:CNMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.